查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466242

皮质类固醇抑制剂市场：按药物、治疗类型、分销管道和最终用户划分 - 全球预测 2024-2030

Adrenal Corticosteroid Inhibitors Market by Drug (Aminoglutethimide, Levoketoconazole, Metyrapone), Treatment Type (Breast Cancer, Cushing's Syndrome, Prostate Cancer), Distribution Channel, End-user - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年皮质类固醇抑制剂市场规模为24.9亿美元，预计2024年将达28亿美元，2030年将达57.8亿美元，复合年增长率为12.75%。

皮质类固醇抑制剂是一组药物化合物，旨在抑制体内皮质醇和其他肾上腺皮质荷尔蒙的产生和抑製作用。肾上腺皮质荷尔蒙是一组主要由位于肾臟上方的肾上腺所产生的荷尔蒙。这些荷尔蒙调节许多生理过程，包括免疫反应、发炎、压力、新陈代谢和血压。肥胖、第2型糖尿病和卵巢症候群等内分泌疾病的流行导致对基于肾上腺皮质荷尔蒙抑制剂的治疗的需求不断增长。然而，医药品认证过程中的监管障碍可能会对寻求核准新药或扩大适应症的製药公司造成严重的时间延误和财务成本。此外，随着疗效、特异性和副作用改善的新药的持续开发，预计将加速全球最终用途部门对皮质类固醇抑制剂的使用。

主要市场统计
基准年[2023] 24.9亿美元
预测年份 [2024] 28亿美元
预测年份 [2030] 57.8亿美元
复合年增长率（%） 12.75%

奥西洛司他药物製剂的使用正在迅速增加。

胺基是一种老一代肾上腺类固醇抑制剂，可阻止肾上腺皮质中胆固醇转化为孕烯醇酮并抑制皮质醇的产生。Ketoconazole是一种新型临床实验药物，透过抑制多种参与类固醇生成的酵素来抑制皮质醇合成，可有效治疗内源性库欣氏症候群。 Metyrapone 是一种皮质类固醇抑制剂，可抑制 11B-氧化酵素（产生皮质醇的酵素）。该药物用作库欣氏症候群急性发作患者的短期治疗选择，或用作确定皮质醇反应性的诊断工具。 Osilodrostat 是一种有效的口服 11B-羟化酶抑制剂，已被证明可以快速、持续地降低库欣氏症患者的平均尿液游离皮质醇。

治疗类型 增加皮质类固醇抑制剂在库欣氏症候群治疗的使用

皮质类固醇抑制剂用于治疗荷尔蒙受体阳性（HR+）转移性乳癌。当Aromatase抑制剂（HR+乳癌的第一线药物）产生抗药性时，就会需要这些抑制剂。皮质类固醇抑制剂在库欣氏症候群的治疗中发挥重要作用，库欣氏症候群是一种由长期暴露于高浓度皮质醇所引起的荷尔蒙失调。这些抑制剂旨在抑制皮质醇的产生并缓解与皮质醇过多相关的症状，例如肥胖、疲劳和高血压。儘管进行了初始荷尔蒙疗法，但晚期前列腺癌常常由于雄性激素的持续产生而进展。皮质类固醇抑制剂，例如醋酸Abiraterone，与皮质类固醇药物泼尼鬆一起使用，以抑制雄激素的产生和癌症的生长。

销售管道：不断发展的皮质类固醇抑制剂线上分销管道

医院药局为医院和诊所收治的患者提供服务，在皮质类固醇抑制剂的分销中发挥重要作用。这些设施通常设有现场药房，以确保药物（包括皮质类固醇抑制剂）的可及性和可用性。医院药局主要直接向製造商和供应商购买药品。近年来，由于人们对宅配服务的日益偏好以及互联网在全球范围内的普及，在线药房迅速普及。网上药局提供送货上门的便利，同时透过直接从製造商和授权经销商处采购来维持品质保证。但是，请警惕一些不受监管的电子商务网站上销售的假药。零售药局仍然是皮质类固醇抑制剂分销管道的重要组成部分，因为它们广泛存在于世界各地的住宅。零售药局可以快速为需要非成药药和处方笺药的顾客提供服务。

最终用户：专门中心大量采用皮质类固醇抑制剂

使用皮质类固醇抑制剂的主要场所是医院，在那里可以提供需要紧急干预的先进诊断工具和综合治疗。患有严重或危及生命的疾病（例如肾上腺腺癌或需要手术的患者）的患者通常在医院接受抑制剂治疗。专科中心专注于为患有特定疾病的患者提供专门护理。当涉及皮质类固醇抑制剂时，这些中心治疗罕见内分泌疾病的患者，专业知识和经验对于处理这些复杂的病例至关重要。

区域洞察

在美洲，我们看到人们对爱迪生氏症、库欣氏症候群和其他肾上腺皮质疾病的认识不断提高，大型製药企业的研究经费不断增加，大型製药企业在欧盟国家，由于人们对肾上腺疾病的早期检测和有效治疗方法的认识不断提高，对皮质类固醇抑制剂的需求正在增加。随着政府投资改善医疗基础设施、提高公众健康意识和促进临床研究活动，欧洲、中东和非洲地区为肾上腺皮质荷尔蒙抑制剂製造商提供了巨大的机会。随着製药公司透过强有力的研发策略开发新型抑制剂以及政府政策鼓励对生物製药製造厂的投资，皮质类固醇抑制剂在亚太地区不断成长。此外，线上药局和分销平台的出现预计将扩大分销并改善肾上腺皮质疾病的治疗效果。

FPNV定位矩阵

FPNV定位矩阵对于评估皮质类固醇抑制剂市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对皮质类固醇抑制剂市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.皮质类固醇抑制剂市场规模及预测是多少？

2.在皮质类固醇抑制剂市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.皮质类固醇抑制剂市场的技术趋势和法规结构是什么？

4.皮质类固醇抑制剂市场主要供应商的市场占有率为何？

5. 进入皮质类固醇抑制剂市场合适的型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 治疗内分泌疾病对皮质类固醇抑制剂的需求不断增加
      • 政府对基于皮质类固醇抑制剂的药物的核准增加
    • 抑制因素
      • 与皮质类固醇抑制剂相关的认知度低且成本高
    • 机会
      • 大量投资皮质类固醇抑制剂的研发
      • 先进医疗设施的增加和製药业的进步
    • 任务
      • 对基于皮质类固醇抑制剂的药物副作用的担忧
  • 市场区隔分析
    • 药物：奥西洛司他药物的使用激增作为疾病的长期治疗选择
    • 治疗类型：增加皮质类固醇抑制剂的使用来治疗库欣氏症候群
    • 交付管道：不断发展的皮质类固醇抑制剂线上交付管道
    • 最终用户：专门中心大量采用皮质类固醇抑制剂
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章皮质类固醇抑制剂市场（依药物）

  • 胺基
  • Ketoconazole
  • 美提拉蓬
  • 振盪器

第七章依治疗类型分類的皮质类固醇抑制剂市场

  • 乳癌
  • 库欣氏症候群
  • 摄护腺癌

第八章皮质类固醇抑制剂市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章皮质类固醇抑制剂市场：依最终用户分类

  • 医院
  • 专业中心

第10章美洲皮质类固醇抑制剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区皮质类固醇抑制剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的皮质类固醇抑制剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Coherus 和君实生物科技宣布 FDA核准LOQTORZI（特瑞普利单抗-tpzi）用于所有復发性或转移性鼻咽癌 (NPC) 治疗线
    • 美国FDA核准双效锭剂AKEEGA（尼拉帕尼和Abiraterone阿比特龙）用于治疗 BRCA 阳性转移性去势抗性前列腺癌患者
    • Moderna 和默克公司宣布，临床实验性个人化 mRNA 癌症疫苗 mRNA-4157/V940 与 KEYTRUDA®（ Pembrolizumab ）联合使用在 2b 期 KEYNOTE-942 研究中达到了主要疗效终点
  • 战略分析和建议

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-FB6C9E792FB6

[184 Pages Report] The Adrenal Corticosteroid Inhibitors Market size was estimated at USD 2.49 billion in 2023 and expected to reach USD 2.80 billion in 2024, at a CAGR 12.75% to reach USD 5.78 billion by 2030.

Adrenal corticosteroid inhibitors are a class of pharmaceutical compounds designed to suppress the production or inhibitory action of cortisol and other corticosteroids within the body. Corticosteroids are a group of hormones that are primarily produced by the adrenal glands that are located above each kidney. These hormones regulate numerous physiological processes such as immune response, inflammation, stress, metabolism, and blood pressure. Prevalence of endocrine diseases, including obesity, type 2 diabetes mellitus, and polycystic ovary syndrome, have contributed to a higher need for Adrenal corticosteroid inhibitor-based therapies. However, regulatory hurdles pertaining to drug approval processes can impose significant time delays and financial costs on pharmaceutical companies seeking approval for new drugs or expanded indications. Furthermore, the ongoing development of new drugs with improved efficacy, specificity, and reduced side effects is anticipated to accelerate the use of adrenal corticosteroid inhibitors by the end-use sectors globally.

KEY MARKET STATISTICS
Base Year [2023] USD 2.49 billion
Estimated Year [2024] USD 2.80 billion
Forecast Year [2030] USD 5.78 billion
CAGR (%) 12.75%

Drug: Burgeoning utilization of osilodrostat drug owing to its long-term treatment option for diseases

Aminoglutethimide is an older-generation adrenal steroid inhibitor that stops the conversion of cholesterol to pregnenolone in the adrenal cortex, thereby reducing cortisol production. Levoketoconazole is a novel investigational drug and shows results in treating endogenous Cushing's syndrome by inhibiting cortisol synthesis by blocking multiple enzymes involved in steroidogenesis. Metyrapone is an adrenal corticosteroid inhibitor that inhibits 11B-hydroxylase, an enzyme in cortisol production. This drug is used as a short-term treatment option for patients experiencing acute episodes of Cushing's syndrome or as a diagnostic tool to determine cortisol responsiveness. Osilodrostat is a potent oral inhibitor of 11B-hydroxylase that has demonstrated rapid and sustained reductions in mean urinary-free cortisol levels in patients with Cushing's disease.

Treatment Type: Increasing use of adrenal corticosteroid inhibitors for treating cushing's syndrome

Adrenal corticosteroid inhibitors are utilized in the treatment of hormone-receptor-positive (HR+) metastatic breast cancer. The need for these inhibitors arises when patients become resistant to aromatase inhibitors, which are the first line of treatment for HR+ breast cancer. Adrenal corticosteroid inhibitors play a critical role in managing Cushing's syndrome, a hormonal disorder caused by prolonged exposure to high levels of cortisol. These inhibitors aim to reduce cortisol production and alleviate symptoms associated with cortisol excess, such as obesity, fatigue, and hypertension. Advanced prostate cancer often progresses despite initial hormone therapy due to the continued production of androgen hormones. Adrenal corticosteroid inhibitors, such as abiraterone acetate, are combined with prednisone, a corticosteroid drug, to suppress androgen production and limit cancer growth.

Distribution Channel: Evolving online distribution channel for adrenal corticosteroid inhibitors

In the distribution of adrenal corticosteroid inhibitors, hospital pharmacies play a crucial role, as they cater to patients admitted in hospitals and clinics. These medical facilities usually have an in-house pharmacy, ensuring the accessibility and availability of medications, including adrenal corticosteroid inhibitors. Hospital pharmacies mainly procure drugs directly from manufacturers or suppliers. With the growing preference for home delivery services, online pharmacies have rapidly gained popularity in recent years due to increasing internet penetration worldwide. Online pharmacies offer convenience through door-to-door deliveries while maintaining quality assurance by sourcing directly from manufacturers or authorized distributors. However, there is a need to be cautious regarding counterfeit drugs sold on some unregulated e-commerce websites. Retail pharmacies remain an integral part of the distribution channel landscape for adrenal corticosteroid inhibitors due to their widespread presence across residential areas worldwide. They serve walk-in customers who require over-the-counter or prescription-based medications promptly.

End-user: Significant adoption of adrenal corticosteroid inhibitors in specialty centers

Hospitals remain a primary setting for administering adrenal corticosteroid inhibitors owing to their ability to provide comprehensive care with access to advanced diagnostic tools and emergency intervention if required. Patients with severe or life-threatening conditions, such as adrenal carcinoma or those requiring surgery, often receive their inhibitor treatments in a hospital setting. Specialty centers focus on providing specialized care to patients with specific medical conditions. In the context of adrenal corticosteroid inhibitors, these centers cater to patients with rare endocrine disorders where expert knowledge and experience are vital in managing these complex cases.

Regional Insights

The adrenal corticosteroid inhibitors market is evolving in the Americas owing to the growing awareness of Addison's disease, Cushing's syndrome, and other adrenocortical disorders, increased research funding from the and collaboration with major pharmaceutical companies facilitating advanced clinical trials and novel drug development. In EU countries, the demand for adrenal corticosteroid inhibitors has escalated due to increased awareness about early detection and effective treatment options for adrenal diseases. The EMEA region represents a significant opportunity for adrenal corticosteroid inhibitor manufacturers as governments invest in improving healthcare infrastructure, raising public health awareness, and promoting clinical research activities. Adrenal corticosteroid inhibitors are growing in the APAC region, with pharmaceutical companies developing novel inhibitors through robust R&D strategies and government policies encouraging investment in biopharmaceutical manufacturing plants. Furthermore, the emergence of online pharmacy and distribution platforms is anticipated to expand the distribution and improve the treatment outcomes of adrenocortical medical conditions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Adrenal Corticosteroid Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Adrenal Corticosteroid Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Adrenal Corticosteroid Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adooq Bioscience LLC, Cayman Chemical Company, Crinetics Pharmaceuticals, Inc., Eli Lilly and Company, Enzo Life Sciences, Inc., Hefei Home Sunshine Pharmaceutical Technology Co., Ltd., HRA Pharma Rare Diseases SAS by Perrigo Company plc, MedChemExpress, Merck KGaA, Novartis AG, Orphagen Pharmaceuticals, Pfizer Inc., Sparrow Pharmaceuticals Inc., Steris Healthcare PVT Ltd, Tocris Bioscience by Bio-Techne Corporation, and Xeris Biopharma Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Adrenal Corticosteroid Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Aminoglutethimide
    • Levoketoconazole
    • Metyrapone
    • Osilodrostat
  • Treatment Type
    • Breast Cancer
    • Cushing's Syndrome
    • Prostate Cancer
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End-user
    • Hospitals
    • Speciality Centres
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Adrenal Corticosteroid Inhibitors Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Adrenal Corticosteroid Inhibitors Market?

3. What are the technology trends and regulatory frameworks in the Adrenal Corticosteroid Inhibitors Market?

4. What is the market share of the leading vendors in the Adrenal Corticosteroid Inhibitors Market?

5. Which modes and strategic moves are suitable for entering the Adrenal Corticosteroid Inhibitors Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing need for adrenal corticosteroid inhibitors to treat endocrine diseases
      • 5.1.1.2. Rising government approvals for adrenal corticosteroid inhibitors-based drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and high cost associated with adrenal corticosteroid inhibitors
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant investments in research and development of adrenal corticosteroid inhibitors
      • 5.1.3.2. Growing presence of refined medical facilities and advances in pharmaceutical sector
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding side impacts of adrenal corticosteroid inhibitors-based drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug: Burgeoning utilization of osilodrostat drug owing to its long-term treatment option for diseases
    • 5.2.2. Treatment Type: Increasing use of adrenal corticosteroid inhibitors for treating cushing's syndrome
    • 5.2.3. Distribution Channel: Evolving online distribution channel for adrenal corticosteroid inhibitors
    • 5.2.4. End-user: Significant adoption of adrenal corticosteroid inhibitors in specialty centers
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Adrenal Corticosteroid Inhibitors Market, by Drug

  • 6.1. Introduction
  • 6.2. Aminoglutethimide
  • 6.3. Levoketoconazole
  • 6.4. Metyrapone
  • 6.5. Osilodrostat

7. Adrenal Corticosteroid Inhibitors Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Cushing's Syndrome
  • 7.4. Prostate Cancer

8. Adrenal Corticosteroid Inhibitors Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Adrenal Corticosteroid Inhibitors Market, by End-user

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Speciality Centres

10. Americas Adrenal Corticosteroid Inhibitors Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Adrenal Corticosteroid Inhibitors Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Adrenal Corticosteroid Inhibitors Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
    • 13.3.2. U.S. FDA Approves AKEEGA (Niraparib and Abiraterone Acetate), the Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
    • 13.3.3. Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ADRENAL CORTICOSTEROID INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ADRENAL CORTICOSTEROID INHIBITORS MARKET DYNAMICS
  • FIGURE 7. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ADRENAL CORTICOSTEROID INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. ADRENAL CORTICOSTEROID INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ADRENAL CORTICOSTEROID INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY AMINOGLUTETHIMIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY AMINOGLUTETHIMIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY LEVOKETOCONAZOLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY LEVOKETOCONAZOLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY METYRAPONE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY METYRAPONE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY OSILODROSTAT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY OSILODROSTAT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY CUSHING'S SYNDROME, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY CUSHING'S SYNDROME, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY SPECIALITY CENTRES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY SPECIALITY CENTRES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA ADRENAL CORT